Table 6—

Therapies proven effective in diabetes prevention trials

Study (ref.)nPopulationMean age (years)Duration (years)Intervention (daily dose)Conversion in control subjects (%/year)Relative risk
Lifestyle
    Finnish DPS (11)522IGT, BMI ≥25 kg/m2553.2Individual diet/exercise60.42 (0.30–0.70)
    DPP (10)2,161*IGT, BMI ≥24 kg/m2, FPG >5.3 mmol/l513Individual diet/exercise100.42 (0.34–0.52)
    Da Qing (12)259*IGT (randomized groups)456Group diet/exercise160.62 (0.44–0.86)
    Toranomon study (28)458IGT (men), BMI = 24 kg/m2554Individual diet/exercise20.33 (0.10–1.0)
    Indian DPP (16)269*IGT462.5Individual diet/exercise220.71 (0.63–0.79)
Medications
    DPP (10)2,155*IGT, BMI >24 kg/m2, FPG >5.3 mmol/l512.8Metformin (1,700 mg)100.69 (0.57–0.83)
    Indian DPP (16)269*IGT462.5Metformin (500 mg)220.74 (0.65–0.81)
    STOP NIDDM (14)1,419IGT, FPG >5.6 mmol/l543.2Acarbose (300 mg)130.75 (0.63–0.90)
    XENDOS (29)3,277BMI >30 kg/m2434Orlistat (360 mg)20.63 (0.46–0.86)
    DREAM (15)5,269IGT or IFG553.0Rosiglitazone (8 mg)90.40 (0.35–0.46)
  • *

    * Number of participants in the indicated comparisons, not necessarily in the entire study.

  • Calculated from information in the article. DPP, Diabetes Prevention Program; DREAM, Diabetes REduction Assessment with ramipril and rosiglitazone Medication; DPS, Diabetes Prevention Study; STOP NIDDM, Study to Prevent Non-Insulin Dependent Diabetes; XENDOS, Xenical in the prevention of Diabetes in Obese Subjects. This table has been reprinted with permission (30) with some modification.